Sébastien Foulquier studied pharmaceutical sciences at the Faculty of Pharmacy of Nancy, France from 2002 until 2008 where he specialized in R&D. He joined the Cardiovascular division of the Servier Research Institute in Suresnes, near Paris for his senior internship before graduating with a Pharm.D. thesis that was awarded by the Faculty as “Best experimental Pharm.D. thesis”. He pursued his studies with a Master in Physiopathology and pharmacology of the cardiovascular system in Lyon, France and a PhD in Cardiovascular Pharmacology at Nancy University, France. During his PhD, he studied the impact of hypertension and the renin angiotensin system on the structure and function of the cerebral circulation in vivo. He completed his PhD in 3 years and got awarded with a prize for the best PhD thesis from the Faculty of Pharmacy. He joined Maastricht University in July 2012 as post-doctoral researcher. Affiliated at both Cardiovascular (CARIM) and Neuroscience (MHeNS) Institutes in Maastricht, he is now leading several research projects on Vascular Cognitive Impairment with a focus on the contribution of vascular risk factors (especially Hypertension) to Blood Brain Barrier dysfunction, Microglial activation and Cognitive dysfunction. He has obtained research grants from the European Society of Hypertension and Servier in 2015, from the Young Talent Program of the Dutch Heart Foundation-CVON “Heart-Brain Connection” in 2016, from the European Foundation for the Study of Diabetes EFSD-Boehringer Ingelheim in 2018 together with Prof C. Schalkwijk and Prof R. van Oostenbrugge. He is furthermore involved in two ongoing European projects: H2020-MSCA-ITN-EJD INTRICARE as PI, and in H2020-PHC SVD@target as participant. He is currently working as Senior Post-doctoral researcher, teaching within the Faculty of Health, Medicine and Life Sciences, pursuing his inter-disciplinary research on Vascular Cognitive Impairment and co-supervising 4 PhD students.
Primary Affiliation: MAASTRICHT UNIVERSITY - MAASTRICHT , Netherlands
aCARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands bKlinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar cDepartment of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany dCardiovascular Medicine, John Radcliffe Hospital, Oxford, UK ePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada fBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.